Fc-Gamma Receptor Polymorphisms Predispose Patients to Infectious Complications after Liver Transplantation

American Journal of Transplantation

Volumn 16, Issue 2, 2016, Pages 625-633

  Shimizu, S ^a   Tanaka, Y ^a   Tazawa, H ^a   Verma, S ^a   Onoe, T ^a,b   Ishiyama, K ^a   Ohira, M ^a   Ide, K ^a   Ohdan, Hideki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

clinical research practice; complication: infectious; genetics; infectious disease; liver transplantation hepatology; liver transplantation: living donor; molecular biology: single polynucleotide polymorphism; natural killer (NK) cells NK receptors; translational research science

Indexed keywords

COTRIMOXAZOLE; FC RECEPTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; ITRACONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; RITUXIMAB; TACROLIMUS; VANCOMYCIN; FCGR3A PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; BLOODSTREAM INFECTION; CYTOMEGALOVIRUS INFECTION; DISEASE PREDISPOSITION; FEMALE; GENETIC POLYMORPHISM; GRAFT REJECTION; HUMAN; INFECTIOUS COMPLICATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOSIS; PNEUMOCYSTOSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADVERSE EFFECTS; COMMUNICABLE DISEASES; COMPLICATION; FOLLOW UP; GENETICS; GRAFT SURVIVAL; LIVER DISEASES; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; COMMUNICABLE DISEASES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, IGG; RISK FACTORS; YOUNG ADULT;

EID: 84957964393     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13492     Document Type: Article

References (44)

1. Al-Hasan MN, Razonable RR, Eckel-Passow JE, Baddour LM., Incidence rate and outcome of Gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant 2009; 9: 835-843.
2. Bodro M, Sabe N, Tubau F, et al., Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. Transplantation 2013; 96: 843-849.
3. Bert F, Larroque B, Paugam-Burtz C, et al., Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: An analysis of 259 episodes. Liver Transplant 2010; 16: 393-401.
4. Iida T, Kaido T, Yagi S, et al., Posttransplant bacteremia in adult living donor liver transplant recipients. Liver Transplant 2010; 16: 1379-1385.
5. Ohira M, Ishiyama K, Tanaka Y, et al., Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest 2009; 119: 3226-3235.
6. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al., Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-3057.
7. Harada N, Shimada M, Okano S, et al., IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J Immunol 2004; 173: 6635-6644.
8. Bruhns P, Iannascoli B, England P, et al., Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113: 3716-3725.
9. Hogarth PM, Pietersz GA., Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nature Rev Drug Discov 2012; 11: 311-331.
10. Bruhns P., Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119: 5640-5649.
11. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M., Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114.
12. van Sorge NM, van der Pol WL, van de Winkel JG., FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003; 61: 189-202.
13. Sole-Violan J, Garcia-Laorden MI, Marcos-Ramos JA, et al., The Fcgamma receptor IIA-H/H131 genotype is associated with bacteremia in pneumococcal community-acquired pneumonia. Crit Care Med 2011; 39: 1388-1393.
14. Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss KD, Bittenbring J., The impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood 2011; 118: 4657-4662.
15. Reid KB., Proteins involved in the activation and control of the two pathways of human complement. Biochem Society Transact 1983; 11: 1-12.
16. Kishore U, Reid KB., C1q: Structure, function, and receptors. Immunopharmacology 2000; 49: 159-170.
17. Racila E, Link BK, Weng WK, et al., A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008; 14: 6697-6703.
18. Trouw LA, Daha N, Kurreeman FA, et al., Genetic variants in the region of the C1q genes are associated with rheumatoid arthritis. Clin Exp Immunol 2013; 173: 76-83.
19. Racila E, Racila DM, Ritchie JM, Taylor C, Dahle C, Weiner GJ., The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics 2006; 58: 1-8.
20. Cartron G, Dacheux L, Salles G, et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758.
21. Ohdan H, Mizunuma K, Tashiro H, et al., Intraoperative near-infrared spectroscopy for evaluating hepatic venous outflow in living-donor right lobe liver. Transplantation 2003; 76: 791-797.
22. Ide K, Tanaka Y, Onoe T, et al., Evidence for the immunosuppressive potential of calcineurin inhibitor-sparing regimens in liver transplant recipients with impaired renal function. J Transplant 2011; 2011: 483728.
23. Tanaka Y, Tashiro H, Onoe T, Ide K, Ishiyama K, Ohdan H., Optimization of immunosuppressive therapy based on a multiparametric mixed lymphocyte reaction assay reduces infectious complications and mortality in living donor liver transplant recipients. Transplant Proc 2012; 44: 555-559.
24. Tanaka Y, Ohira M, Tashiro H, Imamura M, Chayama K, Ohdan H., Impact of alloimmune T cell responses on hepatitis C virus replication in liver transplant recipients. Hum Immunol 2014; 75: 1259-1267.
25. Horan TC, Andrus M, Dudeck MA., CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-332.
26. Kiuchi T, Onishi Y, Nakamura T., Small-for-size graft: Not defined solely by being small for size. Liver Transplant 2010; 16: 815-817.
27. Kim SI, Kim YJ, Jun YH, et al., Epidemiology and risk factors for bacteremia in 144 consecutive living-donor liver transplant recipients. Yonsei Med J 2009; 50: 112-121.
28. Singhal S, Ellis RW, Jones SG, et al., Targeted prophylaxis with amphotericin B lipid complex in liver transplantation. Liver Transplant 2000; 6: 588-595.
29. Yoshizumi T, Shirabe K, Ikegami T, et al., Decreased immunoglobulin G levels after living-donor liver transplantation is a risk factor for bacterial infection and sepsis. Transplant Infect Dis 2014; 16: 225-231.
30. Ikegami T, Shirabe K, Yoshiya S, et al., Bacterial sepsis after living donor liver transplantation: The impact of early enteral nutrition. J Am Coll Surgeons 2012; 214: 288-295.
31. Onoe T, Tanaka Y, Ide K, et al., Attenuation of portal hypertension by continuous portal infusion of PGE1 and immunologic impact in adult-to-adult living-donor liver transplantation. Transplantation 2013; 95: 1521-1527.
32. Tashiro H, Ishiyama K, Ohira M, et al., Impact of adjuvant immunotherapy using liver allograft-derived lymphocytes on bacteremia in living-donor liver transplantation. Transplantation 2011; 92: 575-580.
33. Medzhitov R, Janeway C Jr., Innate immunity. N Engl J Med 2000; 343: 338-344.
34. Sacks SH, Zhou W., The role of complement in the early immune response to transplantation. Nature Rev Immunol 2012; 12: 431-442.
35. de Rooij BJ, van Hoek B, ten Hove WR, et al., Lectin complement pathway gene profile of donor and recipient determine the risk of bacterial infections after orthotopic liver transplantation. Hepatology 2010; 52: 1100-1110.
36. Worthley DL, Johnson DF, Eisen DP, et al., Donor mannose-binding lectin deficiency increases the likelihood of clinically significant infection after liver transplantation. Clin Infect Dis 2009; 48: 410-417.
37. Bouwman LH, Roos A, Terpstra OT, et al., Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 2005; 129: 408-414.
38. Cervera C, Balderramo D, Suarez B, et al., Donor mannose-binding lectin gene polymorphisms influence the outcome of liver transplantation. Liver Transplant 2009; 15: 1217-1224.
39. Curvelo LA, de Mare-Bredemeijer E, de Canck I, et al., Does the donor mannose-binding lectin genotype really predict the risk of bacterial infections after liver transplantation ? Hepatology 2011; 53: 1786-1787.
40. Stein MP, Edberg JC, Kimberly RP, et al., C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest 2000; 105: 369-376.
41. Frank MM, Joiner K, Hammer C., The function of antibody and complement in the lysis of bacteria. Rev Infect Dis 1987; 9 (Suppl 5): S537-S545.
42. Silhavy TJ, Kahne D, Walker S., The bacterial cell envelope. Cold Spring Harbor Perspect Biol 2010; 2: a000414.
43. Joiner KA, Brown EJ, Frank MM., Complement and bacteria: Chemistry and biology in host defense. Annu Rev Immunol 1984; 2: 461-491.
44. van Kessel KP, Bestebroer J, van Strijp JA,. Neutrophil-mediated phagocytosis of Staphylococcus aureus. Frontiers Immunol 2014; 5: 467.